EUVIMEDEUVIMED entdecken
EUVIMED · CrossrefZeitschrift

Clinical Lung Cancer

ISSN 1525-7304 · Elsevier BV

Neueste Artikel

  1. Modified CARG Score-Guided First-Line Treatment in Older or Vulnerable Patients With Advanced Non-Small-Cell Lung Cancer: Results of the Randomized, Phase 2 DURATION Trial (AIO-YMO/TRK-0416)

    Jonas Kuon, Miriam Blasi, FFarastuk Bozorgmehr, Konrad Kokowski, Martin Faehling, Philipp Schütt, Daniel Christoph Christoph, Martin Kimmich, Eva Lotte Buchmeier, Anke Reinacher-Schick, Matthias Ulmer, Christian Meyer zum Büschenfelde, Nicolas Moosmann, Frank Griesinger, Wolfang Schütte, Ludwig Fischer von Weikersthal, Bernd Schmidt, Wolfgang Gleiber, Heinz Kirchen, Martin Wermke, Paul La Rosé, Gerlinde Schmidtke-Schrezenmeier, Jean-Charles Moulin, Michael Boesche, Christian Grohé, Helga Bernhard, Dominik Modest, Christoph Maintz, Marc Alexander Schneider, Rouven Behnisch, Albrecht Stenzinger, Petros Christopoulos, Michael Thomas

    Erschienen: 2026-12DOI: 10.1016/j.cllc.2026.10.004

  2. Detection of Actionable Genomic Alterations beyond EGFR, ALK and ROS1 in Non-Small Cell Lung Carcinoma: A Real-World Evaluation of a Pathology-Led Staggered Reflex Predictive Biomarker Testing Strategy in a Resource-Limited Setting

    Aruna Nambirajan, Kaustar Yadav, Saumya Sahu, Snehvarsha Bhagat, Prajna Gopalakrishna, Shraddanjali Satapathy, Warisa Khatoon, Suyash Devgan, Amita Singh, Aparna Sharma, Anant Mohan, Prabhat Singh Malik, Chitra Sarkar, Deepali Jain

    Erschienen: 2026-12DOI: 10.1016/j.cllc.2026.10.006

  3. Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Post-progression on First-Line Osimertinib: ORCHARD

    Jonathan W. Goldman, Jonathan W. Riess, Byoung Chul Cho, Sarah B. Goldberg, Xiuning Le, Zofia Piotrowska, Isamu Okamoto, Helena A. Yu, Rosario García-Campelo, Javier de Castro Carpeño, Simon Ekman, Noemi Reguart, Marthe S. Paats, Sang-We Kim, Yu Jung Kim, Makoto Nishio, Kristen A. Marrone, Knut B. Smeland, Lizza E.L. Hendriks, Hiroaki Akamatsu, Junichi Shimizu, Paul E. Smith, Kwan Ho Tang, Jonathan M. Lehman, Adrianus J. de Langen

    Erschienen: 2026-11DOI: 10.1016/j.cllc.2026.09.001

  4. A Randomized Phase III Trial of Concurrent Chemoradiotherapy Followed by Durvalumab Consolidation, With or Without Induction Chemo-Immunotherapy, in Patients With Unresectable Locally Advanced Non–Small Cell Lung Cancer: JCOG2510 (PRIME-CRT)

    Kota Kawabata, Ken Masuda, Keita Miura, Yu Saida, Ryo Ko, Hiroaki Akamatsu, Hidehito Horinouchi, Takahito Chiba, Kae Okuma, Hideyuki Harada, Yoshimasa Shiraishi, Yasushi Goto, Shogo Nomura, Noriko Mitome, Haruhiko Fukuda, Isamu Okamoto, Hirotsugu Kenmotsu

    Erschienen: 2026-11DOI: 10.1016/j.cllc.2026.09.007

  5. SAARC Consensus Recommendations for the diagnosis and treatment of non-small-cell lung cancer (NSCLC)

    Kumar Prabhash, Vanita Noronha, Srikant Anne, Ullas Batra, Sneha Bothra, M V Chandrakanth, Qamruzzaman Chowdhary, Arunangshu Das, Adnan Jabbar, Nadarajah Jeyakumaran, AFM Kamaluddin, Akhil Kapoor, Khalid Ahmad Khalid, Sewanti Limaye, Prabhat Malik, Nandini Menon, Bal Krishna Mishra, Goutam Panda, Vijay Patil, K Pavithran, Prabhat Pradhan, Arifur Rahman, Yasmin Abdul Rashid, Wasantha Rathnayake, T P Sahoo, Simit Sapkota, Minit Shah, Ramila Shilpakar, Mostafa Aziz Sumon, Birendra Yadav, Nauman Zahir, Ahmad Javid Zarang

    Erschienen: 2026-11DOI: 10.1016/j.cllc.2026.11.003

  6. Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use

    Utsav Joshi, Faustine Ong, Daniel Melzer, Joanna C. Ma, Andreas Saltos, Alberto Chiappori, Benjamin Creelan, Bruna Pellini, Charles Lu, Eric Haura, Michael Shafique, Tawee Tanvetyanon, Syeda Saba Kareem, Pravash Budhathoki, Daniela C. Bravo Solarte, Syeda Mahrukh Hussnain Naqvi, Omar Castaneda Puglianini, Sameh Gaballa, Jhanelle E. Gray, Sonam Puri

    Erschienen: 2026-03DOI: 10.1016/j.cllc.2025.11.018

  7. Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)

    Yoshihiko Sakata, Go Saito, Shinya Sakata, Teppei Yamaguchi, Motohiro Tamiya, Hidekazu Suzuki, Ryota Shibaki, Asuka Okada, Toshihide Yokoyama, Hirotaka Matsumoto, Taiichiro Otsuki, Yuki Sato, Junji Uchida, Yoko Tsukita, Megumi Inaba, Hideki Ikeda, Daisuke Arai, Hirotaka Maruyama, Satoshi Hara, Shinsuke Tsumura, Jun Morinaga, Takuro Sakagami

    Erschienen: 2025-11DOI: 10.1016/j.cllc.2025.05.015

Jahrgänge

2026 · 1272025 · 2102024 · 1712023 · 1522022 · 1802021 · 2152020 · 1782019 · 1642018 · 1972017 · 1672016 · 1182015 · 1082014 · 842013 · 1132012 · 842011 · 692010 · 632009 · 972008 · 1012007 · 742006 · 762005 · 762004 · 682003 · 672002 · 632001 · 542000 · 631999 · 31

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.